1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s

 
• By Mary Jo Laffler and Sue Sutter

Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few weeks on the US market to surpass total sales of the PCSK9 inhibitors to date.

The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.

Allergan PLC's generic version of AstraZeneca PLC's blockbuster statin Crestor (rosuvastatin) is likely to need only a few...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America